Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targetsAgnieszka K. Witkiewicz, Erik S. Knudsen|Nature Communications|2015Cited by 1.1k
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancerChellappagounder Thangavel, Erik S. Knudsen|Endocrine Related Cancer|2011Cited by 299
Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB PhosphorylationErik S. Knudsen, Jean Y. J. Wang|Molecular and Cellular Biology|1997Cited by 290
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibitionKeelan Z. Guiley, Seth M. Rubin, Kevin Lou et al.|Science|2019Cited by 238
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerJorge Franco, Erik S. Knudsen|Oncotarget|2014Cited by 211